mRNA疫苗生产:挑战与瓶颈
本文综述mRNA疫苗作为新型疫苗平台的技术特点与大规模生产现状。其生产依赖一或两步体外反应及多步纯化平台,包括DNase消化、沉淀、层析或切向流过滤。文章聚焦将mRNA疫苗转化为有效、快速且具成本效益的卫生危机应对手段所需解决的生产挑战与瓶颈。
要点
- mRNA疫苗因精准、安全及灵活生产成为传统疫苗的新替代方案。
- 大规模生产包括一或两步体外反应及多步纯化平台。
- 纯化步骤可包括DNase消化、沉淀、层析或切向流过滤。
核心结论
- mRNA疫苗需解决生产挑战与瓶颈,才能成为有效、快速且具成本效益的卫生危机应对技术。
研究设计与样本
- 综述,描述mRNA疫苗当前技术水平,聚焦生产挑战与瓶颈。
主要发现
- mRNA疫苗因精准、安全及灵活生产而成为传统疫苗的新替代方案。
- mRNA疫苗是许多公司应对Covid-19大流行的首选技术,也是首个在美国和欧盟获批用于预防性治疗的此类技术。
- mRNA疫苗正在临床研究中用于治疗癌症、HIV、流感甚至遗传性疾病。
- mRNA疫苗需求增加要求技术平台与成本效益好的生产工艺,并具备明确的产品表征。
关键数值与推荐
- 大规模生产由一或两步体外反应及多步纯化平台组成,纯化可包括DNase消化、沉淀、层析或切向流过滤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccines are one of the most important tools in public health and play an important role in infectious diseases control. Owing to its precision, safe profile and flexible manufacturing, mRNA vaccines are reaching the stoplight as a new alternative to conventional vaccines. In fact, mRNA vaccines were the technology of choice for many companies to combat the Covid-19 pandemic, and it was the first technology to be approved in both United States and in Europe Union as a prophylactic treatment. Additionally, mRNA vaccines are being studied in the clinic to treat a number of diseases including cancer, HIV, influenza and even genetic disorders. The increased demand for mRNA vaccines requires a technology platform and cost-effective manufacturing process with a well-defined product characterisation. Large scale production of mRNA vaccines consists in a 1 or 2-step in vitro reaction followed by a purification platform with multiple steps that can include Dnase digestion, precipitation, chromatography or tangential flow filtration. In this review we describe the current state-of-art of mRNA vaccines, focusing on the challenges and bottlenecks of manufacturing that need to be addressed to turn this new vaccination technology into an effective, fast and cost-effective response to emerging health crises.
引用
- Rosa SS, Prazeres DMF, Azevedo AM, et al. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine. 2021. PMID: 33771389. doi:10.1016/j.vaccine.2021.03.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。